Vericiguat is being evaluated in the VERINA Study for its efficacy in managing worsening heart failure among patients enrolled in the clinical trial.
In a real-world Indian cohort of patients with worsening HFrEF, vericiguat was successfully titrated to the target dose of 10 mg in over 90% of patients without new safety concerns.
Absolute Event Rate: 0% vs 0%
Clinical Trials Registry of India (CTRI/2022/11/047636).
Abdulakutty et al. (Tue,) reported a other. Vericiguat is being evaluated in the VERINA Study for its efficacy in managing worsening heart failure among patients enrolled in the clinical trial.